The Valley Desk

NCT02073279 · Interventional trial

Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)

Overall registry status Completed

Phase 3

Conditions NMO Spectrum Disorder (NMOSD), Neuromyelitis Optica (NMO)

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov